Aura Biosciences, Inc. (AURA) vs Climb Bio, Inc. (CLYM)

A side-by-side comparison of Aura Biosciences, Inc. and Climb Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Aura Biosciences, Inc. logo
AURA
Aura Biosciences, Inc.
$632M
$6.11HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT
Climb Bio, Inc. logo
CLYM
Climb Bio, Inc.
$630M
$10.99HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT

Total return — AURA vs CLYM

growth of $100 · dividends reinvested · last 2y
AURA -20.1% (-10.6%/yr)CLYM +41.1% (+18.8%/yr)CLYM compounded faster over this window
050100150200Start $10020252026$80$141
AURA CLYM

AURA vs CLYM: by the numbers

  • •AURA is the larger company ($632M vs $630M market cap).

Metrics side by side

Valuation

MetricAURACLYM
P/B ratio2.002.63

Profitability

MetricAURACLYM
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-41.56%-24.06%
ROIC-42.02%-26.94%

Go deeper

Full AURA analysisFull CLYM analysisInteractive comparison tool

Dig into the metrics

Aura Biosciences ROEClimb Bio ROEAura Biosciences operating marginClimb Bio operating marginAura Biosciences revenue growthClimb Bio revenue growthAura Biosciences free cash flowClimb Bio free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.